Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

WuXi Biologics to Build New Biologics Plant Near Boston -- Announces Four New Facilities (a $792 Million Investment) in Two Months

publication date: Jun 11, 2018

WuXi Biologics will invest $60 million to build a state-of-the-art biologics CDMO operation in the greater Boston area, the fourth new manufacturing project WuXi has announced in the last two months. The four most recent projects, representing a total investment of $792 million, are: Ireland ($392 million), Northern China ($240 million), Singapore ($60 million) and now Wooster, Mass, ($60 million), the eleventh CDMO facility in the company's portfolio. The new plants offer geographical diversity. Previously, WuXi Biologics built facilities in Shanghai and Wuxi City. More details....

Stock Symbol: (HK: 2269)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.